Investigational Drug Information for Sitravatinib
✉ Email this page to a colleague
What is the development status for investigational drug Sitravatinib?
Sitravatinib is an investigational drug.
There have been 34 clinical trials for Sitravatinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2022.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Non-Small-Cell Lung, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Mirati Therapeutics Inc., BeiGene, and Zhejiang Cancer Hospital.
There are twenty-eight US patents protecting this investigational drug and three hundred and forty-eight international patents.
Summary for Sitravatinib
| US Patents | 28 |
| International Patents | 348 |
| US Patent Applications | 87 |
| WIPO Patent Applications | 88 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 1 (2022-12-01) |
| Vendors | 48 |
Recent Clinical Trials for Sitravatinib
| Title | Sponsor | Phase |
|---|---|---|
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | BeiGene | Phase 2 |
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | Mirati Therapeutics Inc. | Phase 2 |
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | Grupo Español Multidisciplinar de Melanoma | Phase 2 |
Clinical Trial Summary for Sitravatinib
Top disease conditions for Sitravatinib
Top clinical trial sponsors for Sitravatinib
US Patents for Sitravatinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Sitravatinib | ⤷ Sign Up | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign Up |
| Sitravatinib | ⤷ Sign Up | Methods of treating pediatric cancers | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| Sitravatinib | ⤷ Sign Up | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign Up |
| Sitravatinib | ⤷ Sign Up | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign Up |
| Sitravatinib | ⤷ Sign Up | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | Loxo Oncology, Inc. (Stamford, CT) | ⤷ Sign Up |
| Sitravatinib | ⤷ Sign Up | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sitravatinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Sitravatinib | Australia | AU2016291676 | 2035-07-16 | ⤷ Sign Up |
| Sitravatinib | Brazil | BR112018000808 | 2035-07-16 | ⤷ Sign Up |
| Sitravatinib | Canada | CA2992586 | 2035-07-16 | ⤷ Sign Up |
| Sitravatinib | Chile | CL2018000119 | 2035-07-16 | ⤷ Sign Up |
| Sitravatinib | China | CN108349969 | 2035-07-16 | ⤷ Sign Up |
| Sitravatinib | Denmark | DK3322706 | 2035-07-16 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
